AzTrials
AzTrials

AsthmaRAPIDNCT04287621

Registry of Asthma Patients Initiating DUPIXENT®

An observational study of Asthma, run by Regeneron Pharmaceuticals at 128 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Asthma
What is being tested?
DUPIXENT®
How many people
718 participants
Where
128 sitesin 10 countries
Study dates
2 Mar 2020to 27 Apr 2026
How long will I take part?
156 Weeks
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The target population comprises adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with DUPIXENT® for asthma according to the country-specific prescribing information.

Who may be able to join

  • Willing and able to comply with the required clinic visits, study procedures and assessments
  • Able to understand and complete study-related questionnaires
  • Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required
  • Initiating treatment with DUPIXENT® for a primary indication of asthma according to the country-specific prescribing information

Who cannot join

  • Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
  • Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
  • Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

128 sites in 10 countries.

128 sites in 10 countries

United States73 sites

  • University of Michigan Allergy Specialty Clinic and Food Allergy Clinic

    Ann Arbor, Michigan, 48106

  • University of Michigan

    Ann Arbor, Michigan, 48109

  • Allergy Partners of Western North Carolina

    Asheville, North Carolina, 28801

  • Omni Allergy

    Atlanta, Georgia, 30342

  • Nebraska Medical Research Institute, Inc.

    Bellevue, Nebraska, 68123

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama, 35209

  • Allergy and Asthma Specialists, P.C.

    Blue Bell, Pennsylvania, 19422

  • Treasure Valley Medical Research

    Boise, Idaho, 83706

  • Ocean Allergy & Respiratory Research Center

    Brick, New Jersey, 08724

  • A Atat Progressive Pulmonary & Sleep Medicine

    Brooklyn, New York, 11209

  • Columbo Asthma, Allergy and Immunology, LLC

    Bryn Mawr, Pennsylvania, 19010

  • Allergy Partners of the Triangle

    Cary, North Carolina, 27518

  • UNC Children's Hospital

    Chapel Hill, North Carolina, 27599

  • Javara Inc. and Tryon Medical Partners, PLLC

    Charlotte, North Carolina, 28210

  • Northwestern Medical Group Allergy & Immunology Clinic

    Chicago, Illinois, 60611

  • The University of Chicago

    Chicago, Illinois, 60634

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45220

  • ENT & Allergy Center of Missouri

    Columbia, Missouri, 65201

  • Columbus Regional Research Institute

    Columbus, Georgia, 31904

  • Asthma, Nasal Disease & Allergy Research Center of New England

    East Providence, Rhode Island, 02914

  • NorthShore University Health System

    Evanston, Illinois, 60201

  • Arizona Allergy & Immunology Research

    Gilbert, Arizona, 85234

  • New York Allergy and Sinus Centers

    Glendale, New York, 11385

  • Northwell Health Division of Allergy & Immunology

    Great Neck, New York, 11021

  • Portland Research

    Happy Valley, Oregon, 97086

  • Global Research Solutions

    Hollywood, Florida, 33021

  • Memorial Healthcare System

    Hollywood, Florida, 33021

  • Precision Research Institute, LLC

    Houston, Texas, 77029

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana, 46202

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216

  • Clinical Research Specialists, LLC

    Kissimmee, Florida, 34746

  • Gundersen Health System

    La Crosse, Wisconsin, 54601

  • Tanner Clinic

    Layton, Utah, 84041

  • Family Allergy and Asthma

    Louisville, Kentucky, 40291

  • Northwell Health Physician Partners Pulmonary Medicine and Cardiology at Manhasset

    Manhasset, New York, 11030

  • Allergy and Asthma Center of Minnesota

    Maplewood, Minnesota, 55109

  • NYU Langone Hospital - Long Island

    Mineola, New York, 11501

  • Allergy Associates of Utah

    Murray, Utah, 84107

  • National Allergy and Asthma Research, LLC

    North Charleston, South Carolina, 29420

  • Asthma and Allergy Center of Chicago

    Oak Park, Illinois, 60301

  • Summit Health

    Oakland Gardens, New York, 11364

  • Atlantic Research Center, LLC

    Ocean City, New Jersey, 07712

  • Allergy, Asthma and Clinical Research Center

    Oklahoma City, Oklahoma, 73120

  • Oklahoma Institute of Allergy and Asthma Clinical Research, LLC

    Oklahoma City, Oklahoma, 73131

  • CHI Health Clinic Pulmonary

    Omaha, Nebraska, 68124

  • Children's Hospital of Orange County

    Orange, California, 92868

  • Velocity Clinical Research

    Overland Park, Kansas, 66210

  • Dr. Henry J. Kanarek Allergy, Asthma & Immunology

    Overland Park, Kansas, 66211

  • Allergy & Asthma Specialists, PSC

    Owensboro, Kentucky, 42301

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15212

  • Kratz Allergy & Asthma

    Port Richey, Florida, 34653

  • Riviera Allergy Medical Center

    Redondo Beach, California, 90277

  • IACT Health Southeast Lung Associates

    Rincon, Georgia, 31326

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • RRH Allergy, Immunology & Rheumatology

    Rochester, New York, 14607

  • Schreiber Allergy

    Rockville, Maryland, 20850

  • Allergy & Asthma Care of LI

    Rockville Centre, New York, 11570

  • STAAMP Research, LLC

    San Antonio, Texas, 78229

  • Element Research Group

    San Antonio, Texas, 78258

  • Allergy & Asthma Medical Group and Research, A PC

    San Diego, California, 92123

  • Medical Research of Arizona, a Division of Allergy, Asthma & Immunology Associates, Ltd.

    Scottsdale, Arizona, 85251

  • Seattle Allergy & Asthma Research Institute

    Seattle, Washington, 98115

  • Virgo-Carter Pediatrics

    Silver Spring, Maryland, 20910

  • St. Louis Children's Hospital

    St Louis, Missouri, 63110

  • The Clinical Research Center, LLC

    St Louis, Missouri, 63141

  • GCP, Global Clinical Professionals

    St. Petersburg, Florida, 33702

  • Bensch Clinical Research, LLC

    Stockton, California, 95207

  • Charleston ENT Associates, LLC

    Summerville, South Carolina, 29486

  • Allergy & Asthma Diagnostic Treatment Center

    Tallahassee, Florida, 32308

  • Montefiore Medical Center

    The Bronx, New York, 10461

  • Allianz Research Institute, Inc.

    Westminster, California, 92683

  • Chesapeake Clinical Research, Inc.

    White Marsh, Maryland, 21162

  • Airways Clinical Research Center

    Winston-Salem, North Carolina, 27104

Other trials in United States

Japan12 sites

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-0033

  • Incorporated Medical Corporation, Shishin Iryokai, Respiratory Care Clinic Tokyo

    Chuo-ku, Tokyo, 104-0031

  • Hokkaido University Hospital

    Kita-ku, Hokkaido, 060-8648

  • Hansaki Clinic

    Kiyosu-shi, Aichi-ken, 452-0001

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017

  • Dokkyo Medical University Hospital

    Mibu, Tochigi, 321-0293

  • Incorporated Medical Corporation, Jinyukai, Jinyu Clinic

    Nakano Ku, Tokyo, 164-0012

  • Showa University Hospital

    Shinagawa-ku, Tokyo, 142-8666

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo, 162-8666

  • The Fraternity Memorial Hospital

    Sumida-ku, Tokyo, 130-8587

  • Teikyo University Hospital

    tabashi City, Tokyo, 173-8606

  • Nihon University Itabashi Hospital

    tabashi City, Tokyo, 173-8610

Other trials in Japan

United Kingdom11 sites

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B9 5SS

  • Royal Devon University Healthcare NHS Foundation Trust

    Exeter, EX2 5DW

  • Gartnavel General Hospital

    Glasgow, G12 0YN

  • St. James Hospital Leeds

    Leeds, LS9 7TF

  • Glenfield General Hospital

    Leicester, LE3 9QP

  • St. Bartholomew's Hospital

    London, EC1A 7BE

  • Guy's Hospital

    London, SE1 9RT

  • Pennine Acute Hospitals NHS Trust

    Manchester, Greater Manchester, M8 5RB

  • Wythenshawe Hospital

    Manchester, M23 9QZ

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN

  • Nottingham University Hospitals NHS Trust

    Nottingham, NG5 1PD

Other trials in United Kingdom

Canada7 sites

  • BLC Clinical Research

    Burlington, Ontario, L7N 3V2

  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) - Universite Laval

    Québec, G1V 4G5

  • Evidence Based Medical Educator Inc.

    Toronto, Ontario, M5G 1E2

  • Inspiration Research Limited

    Toronto, Ontario, M5T 3A9

  • The University of British Columbia

    Vancouver, British Columbia, V5Z 1M9

  • St. Paul's Hospital

    Vancouver, British Columbia, V6Z 1Y6

  • Dr. Syeed Anees Medicine Professional Corporation

    Windsor, Ontario, N8X 1T3

Other trials in Canada

Italy7 sites

  • Istituto Nazionale di Riposo e Cura per Anziani

    Ancona, The Marches, 60127

  • Fondazione Salvatore Maugeri

    Bari, Apulia, 70020

  • Azienda Sanitaria Locale Salerno

    Battipaglia, Salerno, 84091

  • Ospedale dei Bambini Vittore Buzzi ASST Fatebenefratelli Sacco

    Milan, Lombardy, 20154

  • Ospedale Luigi Sacco, PU, ASST Fatebenefratelli Sacco

    Milan, Lombardy, 20157

  • La Fondazione IRCCS Policlinico "San Matteo"

    Pavia, Lombardy, 27100

  • Istituto Clinico Himanitas, Humanitas Mirasole S.p.a.

    Rozzano, Lombardy, 20089

Other trials in Italy

France6 sites

  • Centre Hospitalier du Pays d'Aix - Maladies Respiratoires

    Aix-en-Provence, 13100

  • CHU de Bordeaux

    Bordeaux, 33076

  • Centre Hospitalier Universitaire Dijon Bourgogne (CHU Dijon) - Hôpital Francois Mitterrand

    Dijon, 21079

  • Hôpital de la Croix-Rousse

    Lyon, 69317

  • Hôpital Nord

    Marseille, 13015

  • Hopital Jacques Monod

    Montivilliers, 76290

Other trials in France

Puerto Rico6 sites

  • Agosto Allergy and Immunology

    Cayey, 00736

  • CardioPulmonary Research CSP

    Guaynabo, 00968

  • Instituto Pulmonary Diseases Torre Medica San Lucas

    Ponce, 00731

  • Rafael H Zaragoza - Urdaz

    San Juan, 00918

  • Fundacion de Investigacion de Diego

    San Juan, 00927

  • University of Puerto Rico Medical Sciences Campus

    San Juan, 00936

Other trials in Puerto Rico

Spain4 sites

  • Complexo Hospialario Universitario A Coruña

    A Coruña, Galicia, 15006

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Catalonia, 08025

  • Hospital Universitari Vall d'Hebron

    Barcelona, Catalonia, 08035

  • Hospital Germans Trias i Pujol

    Barcelona, Catalonia, 08916

Other trials in Spain

Denmark1 site

  • Sygehus Lillebaelt - Vejle Sygehus - Lungemedicinsk afdeling

    Vejle, 7100

Other trials in Denmark

Sweden1 site

  • Fysikalisk Medicin

    Lidingö, Stockholms Län [se-01], SE-181 58

Other trials in Sweden

About this study

Official title: Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.

This includes characterization of:

Read more
  • Patient demographics (eg, gender, age, and race)
  • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height)

The secondary objectives of the study are:

  • To characterize real-world use patterns of DUPIXENT® for asthma
  • To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting
  • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT®
  • To collect long-term safety data on study participants in the real-world setting
Read the detailed description

3-year registry of real-world use of DUPIXENT® for asthma in patients age 12 and over

Conditions
Asthma
Being tested
DUPIXENT®
Keywords
Primary Indication of Asthma
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DUPIXENT®Drug

    Also called dupilumab, REGN668, SAR231893

    There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Demography

    Including gender, age, race

    Measured: At Baseline

  2. Baseline Characteristics

    Including prior medications and procedures, medical history, asthma history, weight, height

    Measured: At Baseline

Secondary outcomes (14)

  1. Baseline Treatment Characteristics

    Including but not limited to treatment dose, frequency, duration and asthma treatment associations.

    Measured: At Baseline

  2. Incidence of adverse events (AEs)

    Including but not limited to: frequency, percentage and exposure-adjusted incidence rate of AEs

    Measured: Baseline up to 3 years

  3. Physician Assessment: - Spirometry

    Assessment collected as per standard of care. Includes forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory flow (FEF) between 25% to 75% of vital capacity (FEF25%-75%), post-bronchodilator FEV1.

    Measured: Baseline up to 3 years

  4. Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)

    Assessment collected as per standard of care.

    Measured: Baseline up to 3 Years

  5. Patient Reported Outcome: Asthma Control Questionnaire, 6-item (ACQ-6)

    Questionnaire assessing the most common asthma symptoms during the previous week, using a 7-point Likert scale (0=fully controlled; 6=severely uncontrolled). Higher score indicates worse asthma control.

    Measured: Baseline up to 3 Years

  6. Patient Reported Outcome: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)

    Questionnaire answered using a 7-point Likert scale (1=maximum impairment; 7=no impairment). Higher score indicates less impact of asthma on quality of life.

    Measured: Baseline up to 3 Years

  7. Patient Reported Outcome: Global Patient Assessment

    Assessing patient's symptom severity over the past week and the patient's overall satisfaction with their asthma treatment. Higher scores indicate higher severity of asthma symptoms and lower satisfaction with asthma treatment.

    Measured: Baseline up to 3 Years

  8. Patient Reported Outcome: Physical Activity Limitation Questionnaire (PALQ)

    Assessing patient's physical activity in their free time. Higher score indicates more health-related quality of life impairment.

    Measured: Baseline up to 3 Years

  9. Patient Reported Outcome in patients with allergic rhinitis: Allergic Rhinitis Visual Analog Scale (AR-VAS)

    Assessing severity of rhinits symptoms where higher score indicates more bothersome allergic symptoms.

    Measured: Baseline up to 3 Years

  10. Patient Reported Outcome in patients with allergic rhinitis: Standardized Rhinoconjunctivitis Quality of Life Questionnaire for patients 12 years of age and older (RQLQ[S]+12)

    Health-related quality of life signs and symptoms that are most problematic, as a result of perennial or seasonal allergic rhinitis. RQLQ(S)+12 responses are based on 7-point Likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Higher score indicates more health-related quality of life impairment.

    Measured: Baseline up to 3 Years

  11. Patient Reported Outcome in patients with chronic (rhino) sinusitis and/or nasal polyps: Sino-Nasal Outcome Test (SNOT-22)

    Questionnaire to assess the impact of chronic rhinosinusitis on quality of life. Lower score represents better health related quality of life.

    Measured: Baseline up to 3 Years

  12. Patient Reported Outcome in patients with atopic dermatitis: Patient Oriented Eczema Measure (POEM)

    Questionnaire assessing eczema severity with lower score representing impact of lower severity of less severe eczema.

    Measured: Baseline up to 3 Years

  13. Patient Reported Outcome: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-asthma)

    Questionnaire to measure impairments in work and activities with higher score indicating greater impairment and less productivity.

    Measured: Baseline up to 3 Years

  14. Healthcare Utilization: Healthcare Resource Utilization Questionnaire (HCRUQ)

    The HCRUQ collects information on unscheduled healthcare resource encounters related to asthma

    Measured: Baseline up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2020
  2. Study start2 Mar 2020
  3. Primary completion27 Apr 2026
  4. Study completion27 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
718 participants (actual)
Target duration
156 Weeks
IDs, dates and publications
ClinicalTrials.gov ID
NCT04287621
Sponsor's protocol ID
R668-AS-1885
Other IDs
46244, EUPAS41963
Acronym
RAPID
Status last verified
Jun 2026
First submitted
25 Feb 2020
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Peters AT, Cote A, Munoz X, Xia C, Nash S, Hardin M, de Prado Gomez L, Sacks HJ, Jacob-Nara JA, Rowe PJ, Deniz Y. Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry. Adv Ther. 2026 Jul;43(7):3230-3242. doi: 10.1007/s12325-026-03568-6. Epub 2026 Apr 30.

    PubMed 42060163

  • Gall R, Jain N, Soong W, Settipane RA, Xia C, Zhang Y, Haselkorn T, Jacob-Nara JA, Siddiqui S. Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry. Adv Ther. 2023 Mar;40(3):1292-1298. doi: 10.1007/s12325-022-02399-5. Epub 2023 Jan 10.

    PubMed 36626107

Questions about this trial

What is this clinical trial studying?

An observational study of Asthma, run by Regeneron Pharmaceuticals at 128 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 128 sites in United States, Japan, United Kingdom, Canada, Italy and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Demography (time frame: At Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04287621, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in